巴戟天寡糖对抑郁症患者血浆BDNF,GDNF,VEGF和IGF-1水平的影响  

Effects of morinda officinalis oligoseon on plasma levels of BDNF,GDNF,VEGF and IGF-1 in depressed patients

作　　者：邓朔 宓为峰[1] 徐意 李志猛 贾海涛[3] 唐新龙 李玲芝[1] 郭丽华 施莹[1] 张鸿燕[1] DENG Shuo MI Wei-feng XU Yi LI Zhi-meng JIA Hai-tao TANG Xin-long LI Ling-zhi GUO Li-hua SHI Ying ZHANG Hong-yan(Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health （Peking University）, National Clinical Research Center for Mental Disorders （Peking University Sixth Hospital）, Beijing 100191, China Beijing Zhongyan Tongrentang Chinese Medicine R＆D Co. , Ltd. , Beijing 100075, China Bering Minkang Hospital, Beijing 102206, China The Second People＇s Hospital of Lu＇an City, La＇an 237000, China)

机构地区：[1]北京大学第六医院北京大学精神卫生研究所卫生部精神卫生学重点实验室(北京大学)国家精神心理疾病临床医学研究中心(北京大学第六医院),北京100191 [2]北京中研同仁堂医药研发有限公司,北京100075 [3]北京民康医院,北京102206 [4]安徽省六安市第二人民医院,六安237000

出　　处：《中国新药杂志》2017年第20期2454-2458,共5页Chinese Journal of New Drugs

基　　金：国家"重大新药创制"科技重大专项资助项目(2014ZX9301307014)

摘　　要：目的:了解巴戟天寡糖对抑郁症患者血浆脑源性神经营养因子(BDNF)、胶质源性神经营养因子(GDNF)、血管内皮生长因子(VEGF)和胰岛素样生长因子(IGF-1)浓度的影响,探讨巴戟天寡糖治疗抑郁症前后BDNF,GDNF,VEGF和IGF-1的浓度变化与其疗效的关系。方法:本研究入组符合ICD-10的轻中度抑郁症门诊患者32例。入组后单一巴戟天抗抑郁治疗,每2周访视1次,记录患者的抑郁症状及服药情况,共治疗8周,入组前后各采血1次,采用酶联免疫吸附法测定患者血浆BDNF,GDNF,VEGF和IGF-1水平,同时以汉密尔顿抑郁量表(HAMD-17)评定患者的抑郁程度。结果:巴戟天寡糖抗抑郁治疗8周后,HAMD-17总分及各因子分显著降低(P<0.01);巴戟天寡糖治疗8周后,VEGF水平显著下降(Z=-2.354,P<0.05),BDNF和GDNF水平显著上升(Z=-4.157,P<0.01;Z=-4.345,P<0.01),而治疗前后IGF-1水平没有显著变化(Z=-0.901,P>0.05);治疗前后BDNF和GDNF浓度变化率与HAMD-17减分率呈正相关,其相关系数(r)分别为0.782(P<0.01)和0.456(P<0.05),而VEGF与IGF-1浓度变化率与HAMD-17减分率无关(分别为r=0.06,P>0.05;r=0.039,P>0.05)。结论:巴戟天寡糖可以改善BDNF,GDNF和VEGF的异常水平,但对IGF-1水平没有影响。Objective： To investigate the effects of morinda officinalis oligose on plasma levels of BDNF,GDNF,VEGF and IGF-1 in depressed patients.Methods： This study included 32 patients with in mild to moderate depression （ICD-10 critreia）.After entering the group,the patients were provided with antidepressant treatmentwith single Bajitian oligosaccharide capsule,being visited every two weeks to keep a record of depressive symptoms and medication.There are a total of 8 weeks of treatment in each group.And blood samplings are taken before and after the treatment.The BDNF GDNF,VEGF,IGF-1 levels are tested by ELISA adsorption methods,and Hamilton Depression Scale （HAMD-17） is employed to assess the patients＇ depression level.Results： After 8 weeks＇ treatment the HAMD-17 scores and each factor scores declined significantly compared with 0 week （W0） （P〈 0.01）,the plasma levels of VEGF significantly declined （Z =-2.354,P 0.05）,the levels of BDNF and GDNF significantly increased （Z =-4.157,P 0.01） （Z =-4.345,P 0.01）,and the levels of IGF-1 was not significantly different with 0 week （Z =-0.901,P 0.05）.The changes of plasma BDNF and GDNF levels were positively correlated with HAMD-17 reduction ratios （r = 0.782,P 〈 0.01; r = 0.456,P 〉 0.05）,but no correlation was observed between VEGF and IGF-1 change ratio and HAMD-17 reduction ratio （r = 0.06,P 0.05; r = 0.039,P 〉 0.05）.Conclusion： Morinda officinalis oligose can improve abnormal levels of BDNF,GDNF and VEGF,but has no effect on IGF-1 level.

关 键 词：巴戟天寡糖 神经营养因子 抑郁症 

分 类 号：R971.4[医药卫生—药品]